First-in-human Study of S-588210 (S-488210+S-488211)

Lung Cancer Clinical Trial

Official title:

Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04316689
• Other study ID #: 1801P2011
• Status: Completed
• Phase: Phase 1
• Start date: July 30, 2019
• Est. completion date: September 22, 2021

Study information

• Verified date: January 2022
• Source: Shionogi Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 22, 2021
• Est. primary completion date: September 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with unresectable recurrent and/or metastatic solid tumor of lung, esophageal, head and neck, mesothelioma, or bladder cancer (including urothelial cancer of renal pelvis, ureters, and urethra), who have progressed after conventional systemic therapies or have exhausted or are intolerant to existing treatment options.

2. Human leukocyte antigen (HLA)-A*02:01-positive patients.

3. Patients who are male or female aged =18 years at the time of informed consent.

4. Patients with the Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 at enrollment.

5. Patients who have a lymphocyte count accounting for 15% or higher of the total white blood cell count within 28 days before enrollment.

6. Patients who provide a personally signed and dated informed consent document for participation in the study.

7. Patients with expected life-span of at least 3 months from the time of enrollment.

Exclusion Criteria:

1. Patients who are expected to require any of the following therapies between enrollment and completion of the Observation Period.

• Anti-malignant tumor drug
• Systemic corticosteroid (except for corticosteroid defined as the equivalent of prednisone = 10 mg/day orally)
• Systemic immunosuppressant drug
• Radiotherapy (except for restricted radiotherapy for pain relief of bone metastasis) for the cancer(s)
• Surgical therapy for the cancer(s)
• Hyperthermia for the cancer(s)
• Traditional Chinese herbal medicine with anti-tumor or immunosuppressant effect
• Other investigational products

2. Patients who have severe concurrent hepatic impairment, renal impairment, heart disease, hematological disease, respiratory disease, or metabolic disease, with the exception of any symptoms and/or signs associated with cancer(s).

3. Patients who have known human immunodeficiency virus infection.

4. Patients with uncontrolled systemic or active infection.

5. Patients who had any diseases with the risk of sudden death within 12 months before enrollment.

6. Patients with a history or evidence of autoimmune diseases and/or immunodeficiencies.

7. Female patients who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations.

8. Patients who are considered ineligible for this study by the investigator or subinvestigator due to any reasons, including inability to understand and follow the requirements of the study.

Related Conditions & MeSH terms

• Bladder Cancer
• Esophageal Cancer
• Head and Neck Cancer
• Lung Cancer
• Mesothelioma

Intervention

Biological:
• S-488210
S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
• S-488211
S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).

Locations

Country	Name	City	State
United Kingdom	University College London Clinical Research Facility	London

Sponsors (1)

Lead Sponsor	Collaborator
Shionogi

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events	Adverse events will be classified by system organ class and preferred term using Medical Dictionary for Regulatory Activities (MedDRA).	Up to 16 weeks
Secondary	Cytotoxic T Lymphocyte (CTL) Induction Rate	CTL induction is defined as the increase in CTL activity at any point after baseline. Accordingly, the CTL induction rate is calculated as the percentage of participants who show CTL induction to at least any of the 5 antigens.	Baseline and Weeks 8 and 12